Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147794 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL27514296 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL2844018 | 0.86 | SLC7A5 (0.37) | CYP3A4LMNAKMT2AAPPBLM | |
| SCHEMBL5844667 | 0.86 | KIF11 (0.37) | CYP2C19LMNAKMT2AAPPPPARA | |
| SCHEMBL27665873 | 0.86 | DPP4 (0.42) | CYP2D6CYP1A2KMT2AMEN1MAPT | |
| SCHEMBL27564999 | 0.86 | DPP4 (0.42) | CYP2D6CYP1A2KMT2AMEN1MAPT | |
| SCHEMBL4937584 | 0.86 | DPP4 (0.42) | CYP2D6CYP1A2KMT2AMEN1MAPT | |
| SCHEMBL25220978 | 0.85 | SMN1; SMN2 (0.38) | CYP2D6CYP2C19CYP2C9CYP1A2LMNA | |
| SCHEMBL1147857 | 0.85 | APP (0.38) | LMNAKMT2AAPPADRB2 | |
| SCHEMBL27655987 | 0.85 | PDPK1 (0.36) | LMNAGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2025-03-18 | — | — | US | disclosed |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2024-04-04 | — | — | US | disclosed |
| US-11760760-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2023-09-19 | — | — | US | disclosed |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-11236095-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2022-02-01 | — | — | US | disclosed |
| US-20200239483-A1 | PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2020-07-30 | — | — | US | disclosed |
| US-10654855-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2020-05-19 | — | — | US | disclosed |
| US-20180312516-A1 | Protein Kinase B Inhibitors | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | US | disclosed |
| US-10059714-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2018-08-28 | — | — | US | disclosed |
| US-20170057969-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2017-03-02 | — | — | US | disclosed |
| US-9492453-B2 | Protein kinase B inhibitors | ASTRAZENECA AB (SE) | 2016-11-15 | — | — | US | disclosed |
| US-20150182531-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2015-07-02 | — | — | US | disclosed |
| EP-2201012-B1 | PYRROLO[2,3-D]PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS | ASTRAZENECA AB (SE) | 2014-06-25 | — | — | EP | disclosed |
| US-20120190679-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2012-07-26 | — | — | US | disclosed |
| US-8101623-B2 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | ASTRAZENECA AB (SE) | 2012-01-24 | — | — | US | disclosed |
| CN-101861321-A | Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors | ASTRAZENECA AB | 2010-10-13 | — | — | CN | disclosed |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| CN-1882347-A | AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2006-12-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252495-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | CYP3A4 4270/4885CYP2D6 3865/4885CYP2C19 3521/4885 |
| US-20220220116-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | CYP3A4 4270/4885CYP2D6 3865/4885CYP2C19 3521/4885 |
| US-20180312516-A1 | Protein Kinase B Inhibitors | PRKAR2B, PRKCB, AKT1 | CYP3A4 4270/4885CYP2D6 3865/4885CYP2C19 3521/4885 |
| US-10654855-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | CYP3A4 4270/4885CYP2D6 3865/4885CYP2C19 3521/4885 |
| US-20240109902-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | CYP3A4 4270/4885CYP2D6 3865/4885CYP2C19 3521/4885 |
| US-10059714-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | CYP3A4 4270/4885CYP2D6 3865/4885CYP2C19 3521/4885 |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | CYP3A4 4333/4885CYP2D6 4066/4885CYP2C19 4023/4885 |
| US-20170057969-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | CYP3A4 4333/4885CYP2D6 4066/4885CYP2C19 4023/4885 |
| US-20200239483-A1 | PROTEIN KINASE B INHIBITORS | PRKAR2B, PRKCB, AKT1 | CYP3A4 4270/4885CYP2D6 3865/4885CYP2C19 3521/4885 |
| US-20120190679-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | CYP3A4 4333/4885CYP2D6 4066/4885CYP2C19 4023/4885 |
| US-11236095-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | CYP3A4 4270/4885CYP2D6 3865/4885CYP2C19 3521/4885 |
| US-20150182531-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | CYP3A4 4333/4885CYP2D6 4066/4885CYP2C19 4023/4885 |
| US-11760760-B2 | Protein kinase B inhibitors | PRKAR2B, PRKCB, AKT1 | CYP3A4 4270/4885CYP2D6 3865/4885CYP2C19 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.